Table 7 Overview of the protection rate of liver-arresting GAPs in humans
Author | Parasite | Dose | Challenge | Protection |
---|---|---|---|---|
Spring et al., 201335 | PfΔp52Δp36 (2KO) | 5 mosquito bites | NA | NA |
PfΔp52Δp36 (2KO) | 200 mosquito bites | NA | NA | |
Kublin et al., 201741 | PfΔp52Δp36Δsap1 (3KO) | 150–200 mosquito bites | NA | NA |
Murphy et al., 202242 | PfΔp52Δp36Δsap1 (3KO) | 200 mosquito bites 3 times (2 immunizations at monthly intervals and the third 8 weeks later) | 5 PfNF54 mosquito bites 4 weeks later | 3/6 (50%) |
NA | NA | 5 PfNF54 mosquito bites rechallenge 180 days later | 0/3 (0%) | |
PfΔp52Δp36Δsap1 (3KO) | 200 mosquito bites 5 times (4 immunizations at 4-week intervals and the fifth 8 weeks later) | 5 PfNF54 mosquito bites 4 weeks later | 4/8 (50%) | |
NA | NA | 5 PfNF54 mosquito bites rechallenge 180 days later | 1/4 (25%) | |
Roestenberg et al., 202045 | PfΔb9Δslarp (PfSPZ-GA1) | 1.35 × 105 cryopreserved sporozoites IV | NA | NA |
PfSPZ-GA1 | 4.5 × 105 cryopreserved sporozoites IV | NA | NA | |
PfSPZ-GA1 | 9 × 105 cryopreserved sporozoites IV | NA | NA | |
PfSPZ-GA1 | 4.5 × 105 cryopreserved sporozoites IV three time at 2-month intervals | 5 PfNF54 mosquito bites 3 weeks later | 1/12 (8%) | |
PfSPZ-GA1 | 9 × 105 cryopreserved sporozoites IV 3 times at 2-month intervals | 5 PfNF54 mosquito bites 3 weeks later | 2/13 (15%) | |
Lamers et al., 202451 | PfΔmei2 (GA2) | 15 mosquito bites | NA | NA |
PfΔmei2 (GA2) | 50 mosquito bites | NA | NA | |
PfΔb9Δslarp (GA1) | 50 mosquito bites 3 times at monthly intervals | 5 Pf3D7 mosquito bites 3 weeks later | 1/8 (13%) | |
PfΔmei2 (GA2) | 50 mosquito bites 3 times at monthly intervals | 5 Pf3D7 mosquito bites 3 weeks later | 8/9 (89%) | |
Roozen et al., 202552 | PfΔmei2 (GA2) | 50 mosquito bites | 5 Pf3D7 mosquito bites 6 weeks later | 9/10 (90%) |